Research progress in chronic liver disease and iron metabolism

doi:10.3760/cma.j.issn.1007-1245.2023.19.014

International Medicine and Health Guidance News ›› 2023, Vol. 29 ›› Issue (19): 2724-2727.DOI: 10.3760/cma.j.issn.1007-1245.2023.19.014

• New Medical Advances • Previous Articles Next Articles

Research progress in chronic liver disease and iron metabolism

Ma Xiaoying¹, Yang Juan², Zheng Sheng²

¹Graduate Department, Dali University, Dali 671000, China; ²Department of Gastroenterology, The Second Affiliated Hospital of Dali University, The Third People's Hospital of Yunnan Province, Kunming 650011, China

Received:2023-05-03 Online:2023-10-01 Published:2023-11-03
Contact: Zheng Sheng, Email: zheng_sheng523@163.com
Supported by:
Science and Technology Plan Project of Science and Technology Department of Yunnan Province (2018FH001-076, 2018FH001-080); Scientific Research Fund Project of Education Department of Yunnan Province (2023J0926); Eighth Education and Teaching Reform Research Project of Dali University (2022JGYX08-01, 2022JGYX08-02)

慢性肝病与铁代谢的研究进展

马笑盈¹ 杨涓² 郑盛²

¹大理大学研究生部，大理　671000；²大理大学第二附属医院云南省第三人民医院消化内科，昆明　650011

通讯作者: 郑盛，Email：zheng_sheng523@163.com
基金资助:
云南省科技厅科技计划项目（2018FH001-076、2018FH001-080）；云南省教育厅科学研究基金项目（2023J0926）；大理大学第八期教育教学改革研究项目（2022JGYX08-01、2022JGYX08-02）

Abstract

Abstract:

Chronic liver diseases include alcoholic fatty liver, non-alcoholic fatty liver, chronic viral hepatitis B, chronic liver failure, cirrhosis, liver cancer, etc. Liver is an important synthesis, metabolism, and storage organ of iron metabolism. When liver lesions occur, iron metabolism will be impeded, affecting the occurrence and development of various chronic liver diseases. This article reviews the characteristics of iron metabolism in different types of chronic liver diseases.

Key words:

Serum iron, Iron metabolism, Chronic liver diseases, Transferrin, Serum ferritin, Progress

摘要：

慢性肝病包括酒精性脂肪肝、非酒精性脂肪肝、慢性乙型病毒性肝炎、慢性肝衰竭、肝硬化、肝癌等。肝脏是铁代谢的重要合成、代谢、储存器官。当肝脏出现病变时，铁代谢就会发生障碍，影响各种慢性肝病的发生、发展。本文就不同类型慢性肝病的铁代谢特点作一综述。

关键词:

血清铁, 铁代谢, 慢性肝病, 转铁蛋白, 血清铁蛋白, 进展

Ma Xiaoying, Yang Juan, Zheng Sheng.

Research progress in chronic liver disease and iron metabolism [J]. International Medicine and Health Guidance News, 2023, 29(19): 2724-2727.

马笑盈杨涓郑盛.

慢性肝病与铁代谢的研究进展 [J]. 国际医药卫生导报, 2023, 29(19): 2724-2727.

References

[1] Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease[J].Gastroenterology,2020,158(7):1851-1864.DOI:10.1053/j.gastro.2020.01.052.
[2] Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era[J].Haematologica,2020,105(2):260-272. DOI:10.3324/haematol.2019.232124.
[3] Wang Q, Zhu M, Li H, et al. Hyperferritinemia correlates to metabolic dysregulation and steatosis in Chinese biopsy-proven nonalcoholic fatty liver disease patients[J].Diabetes Metab Syndr Obes,2022,15:1543-1552.DOI:10.2147/DMSO.S361187.
[4] He H, Liao S, Zeng Y, et al. Causal relationships between metabolic-associated fatty liver disease and iron status: two-sample Mendelian randomization[J]. Liver Int,2022,42(12):2759-2768.DOI:10.1111/liv.15455.
[5] Wang H, Sun R, Yang S, et al. Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: a systematic review[J]. Front Med (Lausanne),2022,9:934989.DOI:10.3389/fmed.2022. 934989.
[6] Yang N, Lu Y, Cao L, et al. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults[J].J Clin Lab Anal,2022,36(2):e24225.DOI:10.1002/jcla.24225.
[7] Yan JX, Pan BJ, Zhao PP, et al. Serum ferritin is correlated with non-alcoholic fatty liver disease in middle-aged and older patients with type 2 diabetes[J].Endocr Connect,2021,10(12):1560-1569.DOI:10.1530/EC-21-0367.
[8] Pădureanu V, Dop D, Drăgoescu AN, et al. Non-alcoholic fatty liver disease and hematologic manifestations (Review)[J].Exp Ther Med,2021,22(6):1355.DOI:10.3892/etm.2021.10790.
[9] Nikeghbalian S, Rahimi R, Nikoupour H, et al. Correlation between HDL2, HDL3 and serum ferritin levels with fatty liver and NAFLD activity score (NAS) in liver histology of organ donors[J].BMC Gastroenterol,2021,21(1):405.DOI:10.1186/s12876-021-01958-4.
[10] Hu Z, Li Y, Ma B, et al. Iron metabolism mediates the relationship between Vitamin C and hepatic steatosis and fibrosis in NAFLD[J].Front Nutr,2022,9:952056.DOI:10.3389/fnut.2022.952056.
[11] Haghgoo SM, Sharafi H, Alavian SM. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review[J].Clin Chem Lab Med,2019,57(5):577-610.DOI:10.1515/cclm-2018-0357.
[12] Helal MG, El-Kashef DH. Krill oil alleviates oxidative stress, iron accumulation and fibrosis in the liver and spleen of iron-overload rats[J]. Environ Sci Pollut Res Int,2020,27(4):3950-3961.DOI:10.1007/s11356-019- 06983-1.
[13] Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease[J].Clin Liver Dis (Hoboken),2021,17(5):365-370.DOI:10.1002/cld.1061.
[14] Radicheva MP, Andonova AN, Milcheva HT, et al. Serum markers of iron metabolism in chronic liver disease[J]. Open Access Maced J Med Sci,2018,6(6):1010-1016.DOI:10.3889/oamjms.2018.251.
[15] Atkinson SR, Hamesch K, Spivak I, et al. Serum transferrin is an independent predictor of mortality in severe alcoholic hepatitis[J].Am J Gastroenterol,2020,115(3):398-405.DOI:10.14309/ajg.0000000000000492.
[16] Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection[J].Nat Rev Immunol,2022,22(1):19-32.DOI:10.1038/s41577-021- 00549-4.
[17] Wu J, Chen L, Chen Y, et al. Serum ferritin concentration predicts mortality in patients with hepatitis B virus-related acute on chronic liver failure[J].Arch Med Res,2014,45(3):251-256.DOI:10.1016/j.arcmed.2014. 03.004.
[18] Mao W, Hu Y, Lou Y, et al. Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury[J].Eur J Gastroenterol Hepatol,2015,27(2):130-136.DOI:10.1097/MEG.0000000000000247.
[19] Bestas R, Yalcin K. Clinical and virological features of acute hepatic exacerbations in patients with chronic hepatitis B virus infection[J].Cureus,2021,13(6):e15937.DOI:10.7759/cureus.15937.
[20] Çam H, Yılmaz N. Serum hepcidin levels are related to serum markers for iron metabolism and fibrosis stage in patients with chronic hepatitis B: A cross-sectional study[J].Arab J Gastroenterol,2020,21(2):85-90.DOI:10.1016/j.ajg.2020.04.013.
[21] Tey TT, Yiu R, Leow WQ. Hepatitis B-associated symptomatic iron overload, with complete resolution after nucleoside analogue treatment[J].Case Rep Gastrointest Med,2021,2021:8407257.DOI:10.1155/2021/8407257.
[22] Luo J, Liang X, Xin J, et al. Serum ferritin diagnosis and prediction of hepatitis B virus-related acute-on-chronic liver failure[J].J Med Virol,2023,95(1):e28183.DOI:10.1002/jmv.28183.
[23] Yang K, Pan Y, Jin L, et al. Low serum soluble transferrin receptor levels are associated with poor prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J].Biol Trace Elem Res,2023,201(6):2757-2764.DOI:10.1007/s12011-022-03385-2.
[24] Ren P, Wang K, Ma J, et al. Autoantibody against ferritin light chain is a serum biomarker for the detection of liver cirrhosis but not liver cancer[J].J Hepatocell Carcinoma,2022,9:221-232.DOI:10.2147/JHC.S352057.
[25] Tornai D, Antal-Szalmas P, Tornai T, et al. Abnormal ferritin levels predict development of poor outcomes in cirrhotic outpatients: a cohort study[J].BMC Gastroenterol,2021,21(1):94.DOI:10.1186/s12876-021- 01669-w.
[26] 林秋平,甘保波,欧德贵,等. 血清铁蛋白与肝损伤的相关性研究[J]. 中国处方药,2022,20(4):166-168.DOI:10.3969/j.issn.1671-945X.2022.04.069.
[27] Yu YC, Luu HN, Wang R, et al. Serum biomarkers of iron status and risk of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease[J].Cancer Epidemiol Biomarkers Prev,2022,31(1):230-235.DOI:10.1158/1055-9965.EPI-21-0754.
[28] Ülger Y, Delik A. Prognostic value of international normalized ratio-to-albumin ratio and ferritin level in chronic liver patients with hepatocellular carcinoma[J].J Gastrointest Cancer,2022,53(4):1028-1033.DOI:10.1007/s12029-021-00738-3.
[29] Yuan S, Carter P, Vithayathil M, et al. Iron status and cancer risk in UK biobank: a two-sample mendelian randomization study[J].Nutrients,2020,12(2):526.DOI:10.3390/nu12020526.
[30] Kouroumalis E, Tsomidis I, Voumvouraki A. Iron as a therapeutic target in chronic liver disease[J].World J Gastroenterol,2023,29(4):616-655.DOI:10.3748/wjg.v29.i4.616.

Research progress in chronic liver disease and iron metabolism

慢性肝病与铁代谢的研究进展

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	Wang Zechuan, Huang Yueqin. Advances in targeted drug therapy for acute myeloid leukemia [J]. International Medicine and Health Guidance News, 2023, 29(8): 1045-1048.
[2]	Xu Shijie, Luo Zebin, Chen Xiaodong. Application and progress of CT pulmonary angiography in diagnosis and treatment of pulmonary embolism [J]. International Medicine and Health Guidance News, 2023, 29(8): 1053-1056.
[3]	Zhang Heng, Pan Guangtao, Yin Ming, Zhang Ping, Yin Xia. Progress in autologous fat transplantation in plastic surgery [J]. International Medicine and Health Guidance News, 2023, 29(7): 889-892.
[4]	Wu Xuemei, Zhang Yujie, Xie Shenghua. Psoriasis and its cardiovascular system comorbidities [J]. International Medicine and Health Guidance News, 2023, 29(4): 453-456.
[5]	Shang Xue, Zhao Jiahao, Li Xinxi, Zhu Hui, Zhao Ke, Liu Zhenxing, Xu Huipu. Research progress of GSDMD-mediated pyrodeath in atrial fibrillation [J]. International Medicine and Health Guidance News, 2023, 29(20): 2825-2828.
[6]	Wang Yaoyao, Ma Xiufang. Research progress on immune-mediated inner ear disease [J]. International Medicine and Health Guidance News, 2023, 29(20): 2833-2836.
[7]	Wang Lu, Xie Henan, Zhao Qimei, Xie Zheng. Research progress of assessment tools for adults' oral health literacy assessment [J]. International Medicine and Health Guidance News, 2023, 29(20): 2836-2841.
[8]	Chu Linlin, Wang Na, Hao Jiahui, Sun Xiao, Liu Chengxia. Research progress of polyamines and Helicobacter pylori-induced gastric cancer [J]. International Medicine and Health Guidance News, 2023, 29(20): 2848-2851.
[9]	Li Zongrui, Liu Weipeng, Hu Baoguang. Research progress of NKG2D and its ligands in treatment of gastric cancer [J]. International Medicine and Health Guidance News, 2023, 29(20): 2852-2856.
[10]	Yang Lina, Wang Yu, Xia Bo. Research progress on clinical application of Lao Moxibustion [J]. International Medicine and Health Guidance News, 2023, 29(2): 154-.
[11]	Qin Mei, Yuan Xiaoli, Mi Tingtong, Wang Zhenbo. Research progress on the role of β -adrenergic receptor in tumor immunomodulation [J]. International Medicine and Health Guidance News, 2023, 29(19): 2720-2723.
[12]	Yang Xueyuan, Hao Dong. Sepsis and neutrophil function [J]. International Medicine and Health Guidance News, 2023, 29(19): 2728-2732.
[13]	An Jiaqi, Xie Qingzhi. Research progress on the mechanism of sulforaphane in the treatment of digestive system tumors [J]. International Medicine and Health Guidance News, 2023, 29(19): 2732-2736.
[14]	Xie Junli, Zhang Yuerong, Wang Hong. Application of progressive early rehabilitation training in patients after tracheal intubation surgery [J]. International Medicine and Health Guidance News, 2023, 29(19): 2802-2806.
[15]	Yang Jia, Xi Zhefan, Zou Haozhen, Xu Qiang, Dong Hua. Research progress on new immunosuppressive agents in treatment of idiopathic membranous nephropathy [J]. International Medicine and Health Guidance News, 2023, 29(18): 2517-2521.